At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 98 enrolled
Drug / intervention
Slow Infusion of Rubidium-82 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Quantification of Myocardial Blood Flow by 3D Positron Emission Tomography With High and Low Rate Rb82 Infusion Profiles
In Brief
A Phase 4 clinical trial evaluating Slow Infusion of Rubidium-82 for Normal Healthy Volunteers Without Chronic Medical Conditions and 3 related conditions. Completed, enrolled 98 participants across 1 site.
Detailed Summary
The investigators seek to test bolus infusions (50ml/min) vs. slow infusions (20 ml/min) of Rb-82 on metrics of coronary blood flow assessed on a modern 3D PET/CT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNormal Healthy Volunteers Without Chronic Medical Conditions, Coronary Artery Disease, Cardiac Risk Factors, Myocardial Infarction
CountriesUnited States
CollaboratorsBracco Corporate
Timeline
Phase 4CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedMar 2022
Primary CompletionSep 2022
Study CompletionSep 2022
TodayJul 2026
First PostedMar 18, 2022
Enrollment StartDec 28, 2021
Primary CompletionSep 1, 2022
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.3 years ago
Interventions
Slow Infusion of Rubidium-82drug
Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion
Slow Infusion of Rubidium-82drug
Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion
Slow Infusion of Rubidium-82drug
Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion